{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:50:38Z","timestamp":1780447838873,"version":"3.54.1"},"reference-count":84,"publisher":"Frontline Medical Communications, Inc.","issue":"1","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Cutaneous Medicine and Surgery"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.sder.2006.12.002","type":"journal-article","created":{"date-parts":[[2007,3,8]],"date-time":"2007-03-08T12:02:48Z","timestamp":1173355368000},"page":"6-14","source":"Crossref","is-referenced-by-count":46,"title":["Complications and Adverse Reactions in the Use of Newer Biologic Agents"],"prefix":"10.12788","volume":"26","author":[{"given":"Jeffrey P.","family":"Callen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5043","reference":[{"key":"10.1016\/j.sder.2006.12.002_bib1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJM200107263450403","article-title":"Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes","volume":"345","author":"Ellis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sder.2006.12.002_bib2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/archderm.142.2.151","article-title":"Treatment of generalized lichen planus with alefacept","volume":"142","author":"Fivenson","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2006.12.002_bib3","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.bmt.1705185","article-title":"Rapid response to alefacept fiven to patients with steroid resistant or steroid dependent acute graft-versus-host disease: A preliminary report","volume":"36","author":"Shapira","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.sder.2006.12.002_bib4","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/archderm.141.12.1513","article-title":"Alefacept for alopecia areata","volume":"141","author":"Heffrenan","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2006.12.002_bib5","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.clinthera.2005.12.007","article-title":"An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy","volume":"27","author":"Goffe","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.sder.2006.12.002_bib6","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/art.21870","article-title":"Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study","volume":"54","author":"Mease","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.12.002_bib7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.1468-3083.2005.01247.x","article-title":"An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis","volume":"19","author":"Ortonne","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.sder.2006.12.002_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/archderm.138.5.591","article-title":"Psoriasis as a model for T-cell mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab and anti-CDIIa antibody","volume":"138","author":"Gottlieb","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2006.12.002_bib9","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1001\/jama.290.23.3073","article-title":"Efalizumab for patients with moderate to severe plaque psoriasis: A randomized controlled trial","volume":"290","author":"Gordon","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.sder.2006.12.002_bib10","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMoa030002","article-title":"A novel targeted T-cell modulator, efalizumab, for plaque psoriasis","volume":"349","author":"Lebwohl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sder.2006.12.002_bib11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/00128071-200506020-00006","article-title":"Efalizumab","volume":"6","author":"Wellington","year":"2005","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.sder.2006.12.002_bib12","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/archderm.140.10.1287","article-title":"Disseminated granuloma annulare resolved with the T-cell modulator efalizumab","volume":"140","author":"Goffe","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2006.12.002_bib13","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jaad.2005.08.025","article-title":"Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab","volume":"54","author":"Clayton","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2006.12.002_bib14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2340\/00015555-0058","article-title":"Treatment of recalcitrant dermatomyositis with efalizumab","volume":"86","author":"Huber","year":"2006","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.sder.2006.12.002_bib15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/archderm.142.5.555","article-title":"Successful treatment of severe atopic dermatitis in a child and an adult with the T-cell modulator efalizumab","volume":"142","author":"Weinberg","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2006.12.002_bib16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jaad.2006.05.062","article-title":"Treatment of alopecia areata partim universalis with efalizumab","volume":"55","author":"Kaelin","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2006.12.002_bib17","first-page":"77","article-title":"Generalized pustular psoriasis following withdrawal of efalizumab","volume":"3","author":"Gaylor","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.sder.2006.12.002_bib18","first-page":"63","article-title":"Rebound of psoriasis during treatment with efalizumab","volume":"5","author":"Golda","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.sder.2006.12.002_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-5945-5-9","article-title":"Psoriasis vulgaris flare during therapy does not preclude future use: a case series","volume":"5","author":"Lowes","year":"2005","journal-title":"BMC Dermatol"},{"key":"10.1016\/j.sder.2006.12.002_bib20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1517\/14740338.5.2.197","article-title":"Efalizumab: A review of events reported during clinical trials and side effects","volume":"5","author":"Sheinfeld","year":"2006","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.sder.2006.12.002_bib21","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.sder.2006.12.002_bib22","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/art.21946","article-title":"Tumor necrosis factor-neutralizing therapies improve altered hormone axes","volume":"54","author":"Straub","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.12.002_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.sder.2006.12.002_bib24","first-page":"19","volume":"3","author":"Keystone","year":"2005"},{"key":"10.1016\/j.sder.2006.12.002_bib25","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s10227-005-0110-7","article-title":"Off-label uses of anti-TNF-\u03b1 therapies","volume":"9","author":"Alexis","year":"2006","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.sder.2006.12.002_bib26","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1016\/j.jaad.2005.11.1090","article-title":"Case reports of etanercept in inflammatory dermatoes","volume":"54","author":"Norman","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2006.12.002_bib27","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1378\/chest.128.2.1062","article-title":"Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial","volume":"128","author":"Baughman","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.sder.2006.12.002_bib28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","article-title":"Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis","volume":"124","author":"Utz","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.sder.2006.12.002_bib29","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomized trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.sder.2006.12.002_bib30","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: A randomized, double-blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.sder.2006.12.002_bib31","first-page":"273","article-title":"Off-label uses and side effects of infliximab","volume":"3","author":"Scheinfeld","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.sder.2006.12.002_bib32","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1517\/14712598.5.11.1491","article-title":"Adalimumab: An anti-TNF agent for the treatment of psoriatic arthritis","volume":"5","author":"Mease","year":"2005","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.sder.2006.12.002_bib33","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jaad.2006.01.024","article-title":"Treatment of coincident seronegative arthritis and hidradenitis supprativa with adalimumab","volume":"55","author":"Scheinfeld","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2006.12.002_bib34","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/09546630500430604","article-title":"Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent","volume":"16","author":"Callen","year":"2005","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.sder.2006.12.002_bib35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/ard.2005.036434","article-title":"Vaccination against influenza in rheumatoid arthritis: The effect of disease modifying drugs, including TNF alpha blockers","volume":"65","author":"Fomin","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.sder.2006.12.002_bib36","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenecity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sder.2006.12.002_bib37","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.20454","article-title":"Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists","volume":"50","author":"Bergstrom","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.12.002_bib38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Like etanercept, infliximab appears to be have positive effects without excessive toxicity in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis who have a concomitant infection with hepatitis C virus","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.sder.2006.12.002_bib39","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/ard.62.11.1078","article-title":"Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection","volume":"62","author":"Peterson","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"Suppl II","key":"10.1016\/j.sder.2006.12.002_bib40","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.028209","article-title":"Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: Hepatitis C, hepatitis B and HIV infection","volume":"63","author":"Calabrese","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.sder.2006.12.002_bib41","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.4065\/75.10.1093","article-title":"Etanercept for the treatement of human immunodeficiency virus-associated psoriatic arthritis","volume":"75","author":"Aboulafia","year":"2000","journal-title":"Mayo Clin Porc"},{"key":"10.1016\/j.sder.2006.12.002_bib42","first-page":"407","article-title":"Infliximab in the treatment of an HIV positive patient with Reiter\u2019s syndrome","volume":"30","author":"Gaylis","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.sder.2006.12.002_bib43","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18, 572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.12.002_bib44","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.22056","article-title":"Tumor necrosis factor a antagonist use and cancer in patients with rheumatoid arthritis","volume":"54","author":"Setoguchi","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.12.002_bib45","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/archderm.141.7.861","article-title":"No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving ertanercept for up to 5 years","volume":"141","author":"Lebwohl","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2006.12.002_bib46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener\u2019s granulomatosis","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sder.2006.12.002_bib47","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.sder.2006.12.002_bib48","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005176-200502000-00026","article-title":"Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease","volume":"40","author":"Thayu","year":"2005","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.sder.2006.12.002_bib49","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(02)07714-0","article-title":"Drug-induced systemic lupus erythematosus associated with etanercept","volume":"359","author":"Shakoor","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.sder.2006.12.002_bib50","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/art.10271","article-title":"Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: Comment on the article by Pisetsky and the letter from Aringer et al","volume":"46","author":"Fautrel","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.12.002_bib51","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1191\/0961203305lu2240rr","article-title":"The effect of TNF-alpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications","volume":"14","author":"De Rycke","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.sder.2006.12.002_bib52","first-page":"24","article-title":"Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy","volume":"33","author":"Comby","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.sder.2006.12.002_bib53","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis alpha therapy: A French national survey","volume":"7","author":"De Brandt","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.sder.2006.12.002_bib54","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1002\/art.22054","article-title":"IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis","volume":"54","author":"Visvanathan","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.12.002_bib55","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/00005176-200405000-00008","article-title":"Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab","volume":"38","author":"Miele","year":"2004","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.sder.2006.12.002_bib56","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.12.002_bib57","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1540-9740.2005.04502.x","article-title":"TNF-alpha inhibitors and congestive heart failure","volume":"4","author":"Benham","year":"2005","journal-title":"Skinmed"},{"key":"10.1016\/j.sder.2006.12.002_bib58","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.sder.2006.12.002_bib59","series-title":"MedWatch","article-title":"Warning on severe hepatotoxicity with Remicade","year":"2004"},{"key":"10.1016\/j.sder.2006.12.002_bib60","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2230.2006.02086.x","article-title":"Hepatitis: A rare, but important, complication of infliximab therapy for psoriasis","volume":"31","author":"Wahie","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.sder.2006.12.002_bib61","unstructured":"Tobon GJ, Canas C, Jaller JJ, et al: Serious liver disease induced by infliximab. Clin Rheumatol, in press"},{"key":"10.1016\/j.sder.2006.12.002_bib62","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1034\/j.1600-0609.2003.00115.x","article-title":"Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor","volume":"71","author":"Kuruvilla","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.sder.2006.12.002_bib63","doi-asserted-by":"crossref","first-page":"W","DOI":"10.7326\/0003-4819-139-3-200308050-00021-w4","article-title":"Severe neutropenia and thrombocytopenia associated with infliximab","volume":"139","author":"Vidal","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.sder.2006.12.002_bib64","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/ard.2005.037424","article-title":"New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists","volume":"65","author":"Kary","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.sder.2006.12.002_bib65","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/art.21233","article-title":"Psoriasis induced by anti-tumor necrosis factor therapy","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.12.002_bib66","first-page":"1955","article-title":"Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents","volume":"31","author":"Mohan","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.sder.2006.12.002_bib67","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archderm.142.2.198","article-title":"Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors","volume":"142","author":"Deng","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2006.12.002_bib68","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated successfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.12.002_bib69","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.clinthera.2004.12.019","article-title":"Anakinra: review of recombinant human interleukin-1-receptor antagonist in the treatment of rheumatoid arthritis","volume":"26","author":"Furst","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.sder.2006.12.002_bib70","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMoa055137","article-title":"Neonatal-onset multisystem inflammatory disease responsive to interleukin-1b inhibition","volume":"355","author":"Goldbach-Mansky","year":"2006","journal-title":"N Eng J Med"},{"key":"10.1016\/j.sder.2006.12.002_bib71","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5070\/D34NS1K655","article-title":"A review of rituximab in cutaneous medicine","volume":"12","author":"Scheinfeld","year":"2006","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.sder.2006.12.002_bib72","first-page":"34","article-title":"Rituximab (Rituxan) for rheumatoid arthritis","volume":"48","year":"2006","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.sder.2006.12.002_bib73","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jaad.2006.05.009","article-title":"Rituximab: A monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris","volume":"55","author":"El Tal","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2006.12.002_bib74","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2230.2006.02151.x","article-title":"Rituximab in refractory autoimmune bullous diseases","volume":"31","author":"Schmidt","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.sder.2006.12.002_bib75","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/01.bor.0000172798.26249.fc","article-title":"Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future","volume":"17","author":"Sfikakis","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.sder.2006.12.002_bib76","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.berh.2005.05.006","article-title":"New treatments for SLE: Cell-depleting and anti-cytokine therapies","volume":"19","author":"Anolik","year":"2005","journal-title":"Cest Pract Res Clin Rhe"},{"key":"10.1016\/j.sder.2006.12.002_bib77","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/rheumatology\/kel162","article-title":"Therapy-resistant lupus skin disease successfully treated with rituximab","volume":"45","author":"Risselada","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.sder.2006.12.002_bib78","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2006-01-0233","article-title":"Rituximab for steroid-refractory chronic graft-versus-host disease","volume":"108","author":"Cutler","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.sder.2006.12.002_bib79","unstructured":"Stasi R, Stipa E, Poeta GD, et al: Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology, in press"},{"key":"10.1016\/j.sder.2006.12.002_bib80","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1001\/archderm.142.11.1407","article-title":"Successful use of rituximab for cutaneous vasculitis","volume":"142","author":"Chung","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2006.12.002_bib81","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00432-001-0313-2","article-title":"Complete remission of primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab","volume":"128","author":"Bonnekoh","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.sder.2006.12.002_bib82","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2006.12.002_bib83","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2169\/internalmedicine.45.1590","article-title":"Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab","volume":"45","author":"Sera","year":"2006","journal-title":"Intern Med"},{"key":"10.1016\/j.sder.2006.12.002_bib84","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/07357900600815232","article-title":"Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis","volume":"24","author":"Coiffier","year":"2006","journal-title":"Cancer Invest"}],"container-title":["Seminars in Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S108556290600112X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S108556290600112X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scmsjournal.com\/wp-content\/uploads\/2016\/08\/v26i1-Callen.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T20:47:09Z","timestamp":1628542029000},"score":1,"resource":{"primary":{"URL":"http:\/\/scmsjournal.com\/article\/buy_now\/?id=376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S108556290600112X"],"URL":"https:\/\/doi.org\/10.1016\/j.sder.2006.12.002","relation":{},"ISSN":["1085-5629"],"issn-type":[{"value":"1085-5629","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}